David D'Alessio, M.D.
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, David D'Alessio, M.D. sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
David D'Alessio, M.D.: 4 sponsored US clinical trials, 1 recruiting.
David D'Alessio, M.D. sponsors 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Diabetes (DM), with 1 trials.
Upper-quartile sponsor footprint
David D'Alessio, M.D. sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance.
NCT07224334
Glucagon Regulation of Glucose Metabolism
NCT04347252
DPP4 Inhibition & Beta Cell Function
NCT02683187
Incretin Action in Physiology and Diabetes
NCT02550548
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
Therapeutic Areas
What is open in the David D'Alessio, M.D. pipeline
1 recruiting of 4 indexed (25% open); 3 completed (75%).
Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Diabetes (DM) (1 trial), 0 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
David D'Alessio, M.D.: open-pipeline peers nationwide
Peers matched on 4 registered trials and 25% open enrollment, not the therapeutic-area sidebar.
David D'Alessio, M.D. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 25% open enrollment (± trial volume)
- AB Science · 25% recruiting · 8 trials
- Abbott Point of Care · 25% recruiting · 8 trials
- Accutar Biotechnology · 25% recruiting · 4 trials
- Adrienne G. Waks · 25% recruiting · 4 trials
Related
What to do with this David D'Alessio, M.D. page
4 registered trials is a research-attention snapshot, not an endorsement of David D'Alessio, M.D. or any single study.
- 1 of David D'Alessio, M.D.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Diabetes (DM) is the condition David D'Alessio, M.D. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Diabetes (DM) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. David D'Alessio, M.D. pipeline card: 4 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.